Calcium Channel Blocker, Azelnidipine, Reduces Lipid Hydroperoxides in Patients with Type 2 Diabetes Independent of Blood Pressure

• Published in: ENDOCRINE JOURNAL Vol. 54; no. 5; pp. 805 - 811
• Main Authors: CHIE OHMURA, HIROTAKA WATADA, TOMOAKI SHIMIZU, KEN SAKAI, HIROSHI UCHINO, YOSHIO FUJITANI, AKIO KANAZAWA, TAKAHISA HIROSE, RYUZO KAWAMORI
• Format: Journal Article
• Language: Japanese
• Published: The Japan Endocrine Society 2007
• ISSN: 0918-8959

Anti-hypertensive agents with antioxidative effects are plotentially usefUl for diabetic patients with hypertension to prevent the onset and progression of their complication. while dihydropyridine-type calcium antagonists are arnong the frequently used anti-hypertensive drugs, azelnidipine, a novel calcium antagonist, has been reported to have a unique anti-oxidative effect in vitro and in animals. In this study, we measured lipid hydroperoxides in human sample using diphenyl-1-pyrenylphosphine for the first time, and used the value of lipid hydroperoxides as an index of oxidative stress. Then, we compared the antioxidative properties of azelnidipine and amlodipine, a frequently used calcium antagonist in hypertensive diabetic patients. Admirtistration of vitamin C and E for 8 weeks significantly reduced lipid hydroperoxides in erythrocyte membrane in normal subjects. In hypertensive diabetic patients, azelnidipine treatment for 12 weeks induced a more significant fall in erythrocyte lipid hydroperoxide level than amlodipine, though blood pressure during each treatment was comparable. Our data confirm the usefulness of lipid hydroperoxides in erythrocyte membrane as a marker of oxidative stress in vivo, and indicate that azelnidipine has a unique antioxidative property in human.